-Tisagenlecleucel (Kymriah) has been approved for the treatment of relapsed or refractory DLBCL and pediatric/young adult acute lymphoblastic leukemia (ALL). T cells are engineered to express a CAR that specifically targets CD19, leading to the destruction of CD19-positive B cells. -Axicabtagene Ciloleucel (Yescarta) is approved for the treatment of relapsed or refractory large B-cell lymphoma, including DLBCL, primary mediastinal large B-cell lymphoma, and transformed follicular lymphoma. Similar to Kymriah, Yescarta involves engineering T cells to target CD19, enhancing the immune system's ability to eliminate cancerous B cells. -Lisocabtagene Maraleucel (Breyanzi) is approved for the treatment of relapsed or refractory large B-cell lymphoma. It is another CAR-T therapy targeting CD19, designed to provide a robust and durable response in B-cell lymphoma patients. Monoclonal antibodies and antibody-drug conjugates: